δ-Opioid receptor as a target for the creation of peptide drugs that increase cardiac resistance to reperfusion-Reference-Cited by-同舟云学术

δ-Opioid receptor as a target for the creation of peptide drugs that increase cardiac resistance to reperfusion

Published:2023-08-14 Issue: Volume: Page:
ISSN:2713-265X
Container-title:The Siberian Journal of Clinical and Experimental Medicine
language:
Short-container-title:SJCEM

Author:

Mukhomedzyanov A. V.¹^ORCID,Popov S. V.¹^ORCID,Naryzhnaya N. V.¹^ORCID,Sirotina M. А.¹^ORCID,Maslov L. N.¹^ORCID,Kurbatov B. K.¹^ORCID,Gorbunov A. S.¹^ORCID,Kilin M.¹^ORCID,Kan A.²^ORCID,Krylatov A. V.¹^ORCID,Podoksenov Yu. K.¹^ORCID,Azev V. N.³^ORCID,Lasukova T. V.²^ORCID,Sufianova G. Z.⁴^ORCID,Khlestkina M. S.⁴^ORCID

Affiliation:

1. Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences

2. Siberian State Medical University of the Ministry of Health of the Russian Federation

3. Branch of the Shemyakin – Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

4. Tyumen State Medical University

Abstract

An analysis of published data and the results of our own studies showed that activation of peripheral δ2-opioid receptor (δ2-OR) increases cardiac tolerance to reperfusion. It has been established that this δ2-OR is localized in cardiomyocytes. Endogenous opioids are not involved in the regulation of cardiac resistance to reperfusion in non-adapted rats. The infarct-limiting effect of δ2-OR agonist deltorphin II depends on the activation of following protein kinases: PKCδ, ERK1/2, PI3K, PCG. SarcKATP channel and MPT pore are hypothetical end effectors of the cardioprotective effect of deltorphin II.

Publisher

Cardiology Research Institute

Subject

Cardiology and Cardiovascular Medicine,Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,Medicine (miscellaneous),Internal Medicine

Reference42 articles.

1. Megaly M., Pershad A., Glogoza M., Elbadawi A., Omer M., Saad M. et al. Use of intravascular imaging in patients with ST-segment elevation acute myocardial infarction. Cardiovasc. Revasc. Med. 2021;30:59–64. DOI: 10.1016/j.carrev.2020.09.032.

2. Ya'qoub L., Gad M., Saad A.M., Elgendy I.Y., Mahmoud A.N. National trends of utilization and readmission rates with intravascular ultrasound use for ST-elevation myocardial infarction. Catheter. Cardiovasc. Interv. 2021;98(1):1–9. DOI: 10.1002/ccd.29524.

3. Garcia S., Schmidt C.W., Garberich R., Henry T.D., Bradley S.M., Brilakis E.S. et al. Temporal changes in patient characteristics and outcomes in ST-segment elevation myocardial infarction 2003–2018. Catheter. Cardiovasc. Interv. 2021;97(6):1109–1117. DOI: 10.1002/ccd.28901.

4. Maslov L.N., Popov S.V., Mukhomedzyanov A.V., Naryzhnaya N.V., Voronkov N.S., Ryabov V.V. et al. Reperfusion cardiac injury: Receptors and the signaling mechanisms. Curr. Cardiol. Rev. 2022;18(5):63–79. DOI: 10.2174/1573403X18666220413121730.

5. Acharya D. Predictors of outcomes in myocardial infarction and cardiogenic shock. Cardiol. Rev. 2018;26(5):255–266. DOI: 10.1097/CRD.0000000000000190.